

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the announcement (the “**Announcement**”) of Alphamab Oncology (the “**Company**”) dated April 8, 2026 in relation to, among others, change of joint company secretary of the Company.

Pursuant to Rule 8.17 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience.

As stated in the Announcement, Ms. JIANG Rui (蔣銳) (“**Ms. Jiang**”) currently does not possess the relevant academic or professional qualifications or relevant experience as required under the Listing Rules. The Company has made an application to the Stock Exchange for a waiver (the “**Waiver**”) from the strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules.

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company hereby announces that the Stock Exchange has granted the Waiver, which is valid for a period of three years from the date of Ms. Jiang’s appointment as a joint company secretary (the “**Waiver Period**”), on the following conditions:

- (i) Ms. Jiang must be assisted by Ms. CHAN Lok Yee (“**Ms. Chan**”) during the Waiver Period; and
- (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

The Company should announce the reasons for, and details and conditions of the Waiver, and the qualifications and experience of both Ms. Jiang and Ms. Chan. For details of qualifications and experiences of Ms. Jiang and Ms. Chan, please refer to the Announcement.

Before the end of the Waiver Period, the Company must demonstrate to the Stock Exchange and seek confirmation from the Stock Exchange that Ms. Jiang, having had the benefit of Ms. Chan's assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 such that a further waiver will not be necessary.

The Waiver applies to Ms. Jiang's appointment only. The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

With the Waiver granted, the Board is pleased to announce that Ms. Jiang has been appointed as a joint company secretary of the Company with effect from April 8, 2026.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, April 22, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.